Validity and Reliability of the Hypertonia Assessment Tool (HAT) in Stroke Patients (NCT07429383) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Validity and Reliability of the Hypertonia Assessment Tool (HAT) in Stroke Patients
Turkey (Türkiye)60 participantsStarted 2026-03-01
Plain-language summary
In this study, the validity and reliability of the Hypertonia Assessment Tool (HAT), which has previously been validated in the pediatric cerebral palsy (CP) population, will be evaluated in adult individuals who have experienced a stroke. The HAT is a specific clinical instrument designed to differentiate subtypes of hypertonia, including spasticity, dystonia, and rigidity.
Accurate classification of hypertonia subtypes following stroke is crucial for guiding rehabilitation strategies. However, the HAT has not yet been validated in the adult post-stroke population. This study will be conducted at the Physical Medicine and Rehabilitation Clinic of SBU Fatih Sultan Mehmet Training and Research Hospital. The study aims to evaluate the validity and reliability of the HAT for use in adults with stroke.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18 years and older
* Clinically and radiologically confirmed diagnosis of stroke (ischemic or -hemorrhagic)
* Brunnstrom stage between 2 and 6
* Presence of post-stroke hypertonia (spasticity, dystonia, or rigidity)
* Cognitive level sufficient to cooperate with assessments (Mini-Mental State Examination (MMSE) score \>23 or equivalent clinical evaluation)
* Provision of written informed consent
Exclusion Criteria:
* Age under 18 years
* Presence of severe accompanying neurodegenerative diseases (e.g., Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis)
* Presence of primary musculoskeletal disorders affecting motor performance (e.g., rheumatologic diseases, fractures)
* Brunnstrom stage of 1
* Severe aphasia, impaired consciousness, or cognitive deficits preventing effective communication and cooperation
* Any psychiatric disorder that may interfere with study participation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Validity and Reliability of the Hypertonia Assessment Tool (HAT) in Adult Post-Stroke Patients
Timeframe: Baseline assessment and repeat assessment within 2-5 days
Trial details
NCT IDNCT07429383
SponsorFatih Sultan Mehmet Training and Research Hospital